Welcome to our dedicated page for Nemaura Med news (Ticker: NMRD), a resource for investors and traders seeking the latest updates and insights on Nemaura Med stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nemaura Med's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nemaura Med's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nemaura Medical, Inc. (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will engage in a fireside chat on March 29, 2023, at 10 AM ET, hosted by EF Hutton's analyst Constantine Davides. The chat will explore Nemaura's innovative glucose monitoring device, digital health solutions, commercial strategy, and early patient data from their UK pilot program.
The company is developing non-invasive wearable sensors and has submitted a PMA for its sugarBEAT® device to the FDA. Nemaura aims to capitalize on a growing global diabetes market projected to reach nearly $59 billion by 2025.
Nemaura Medical (NASDAQ: NMRD) announced the inclusion of injectable insulin in its DuoPack Commercial License Agreement with MySugarWatch DuoPack Limited. This agreement allows Nemaura's non-invasive wearable sensors to be paired with insulin and other Type 2 diabetes medications, enhancing patient care through a holistic approach. The collaboration aims to provide access to a continuous glucose monitoring-guided insulin dosage system, potentially reducing hospital admissions and improving outcomes for approximately 4 million older diabetes patients in the UK and EU. Nemaura continues to innovate in the diabetes management market, expected to exceed $59 billion by 2025.
FAQ
What is the current stock price of Nemaura Med (NMRD)?
What is the market cap of Nemaura Med (NMRD)?
